CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT06128044
Trial Phases:	Phase I	Protocol IDs:	CB12A (primary) NCI-2024-01081
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Caribou Biosciences, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT06128044

Summary

CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets
C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety,
preliminary efficacy, and pharmacokinetics, of CB-012 (the study treatment) in adults
with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or
did not respond or is no longer responding to other treatment (refractory). Participants
must have received at least 1 but not more than 3 prior lines of treatment for AML .

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.